Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clomiphene Citrate,Dehydroepiandrosterone,Pregnenolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MangoRx to Launch "MOJO" for Low Testosterone & Hormone Imbalances
Details : Mojo (enclomiphene citrate, pregnenolone and dehydroepiandrosterone) is an oral dissolvable tablet aimed at restoring hormonal balance and naturally increasing testosterone levels in men.
Product Name : Mojo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2024
Lead Product(s) : Clomiphene Citrate,Dehydroepiandrosterone,Pregnenolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Clomiphene Citrate
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Jay Pharma received institutional review board approval by Rabin Medical Center in Petah Tikva, Israel for a Phase I/II clinical trial investigating Jay Pharma's proprietary cannabidiol formulation for the treatment of glioblastoma multiforme.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 06, 2020
Lead Product(s) : Cannabidiol,Clomiphene Citrate
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable